Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Restenosis--an open file

M Gottsauner-Wolf1, D J Moliterno, A M Lincoff

  • 1Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA.

Clinical Cardiology
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.

Alimentary pharmacology & therapeutics·2018
Same author

Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Clinical experience with abciximab during coronary revascularisation: an overview.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk.

Heart (British Cardiac Society)·2006
Same author

Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment.

Heart (British Cardiac Society)·2005
Same author

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.

Journal of thrombosis and haemostasis : JTH·2005
Same journal

In-Hospital Cardiac Arrest Detection Performance Analysis and Comparison on Effective Feature Selection.

Clinical cardiology·2026
Same journal

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy.

Clinical cardiology·2026
Same journal

Heart Failure With Preserved Ejection Fraction-Like Phenotype in Coronary Artery Disease and Obstructive Sleep Apnea: Insights From the RICCADSA Cohort.

Clinical cardiology·2026
Same journal

Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.

Clinical cardiology·2026
Same journal

Methodological Considerations Regarding Diuretic Intensity Score and Mortality in Hospitalized Heart Failure Patients.

Clinical cardiology·2026
Same journal

Inpatient Outcomes and Complications After Left Atrial Appendage Occlusion in Rural Versus Urban Hospitals in the United States.

Clinical cardiology·2026
See all related articles

Percutaneous coronary angioplasty restenosis remains a challenge, affecting one-third to one-half of patients. Novel therapies like glycoprotein IIb/IIIa inhibitors and stents show promise in reducing restenosis recurrence.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Restenosis, the re-narrowing of a treated coronary artery segment, is a primary limitation of percutaneous coronary angioplasty (PCA).
  • Despite technological advancements, restenosis affects 33-50% of patients within six months, driven by plaque persistence, thrombus formation, and cellular proliferation.
  • Understanding the biological mechanisms of restenosis is crucial for developing effective prevention strategies.

Purpose of the Study:

  • To review the mechanisms underlying restenosis following percutaneous coronary angioplasty.
  • To evaluate the efficacy of emerging pharmacologic and mechanical therapies in preventing restenosis recurrence.
  • To discuss the potential of future treatments for complete prevention of stenosis recurrence.

Related Experiment Videos

Main Methods:

  • Review of animal models to elucidate restenosis mechanisms.
  • Analysis of clinical trial data for pharmacologic agents and mechanical devices.
  • Evaluation of glycoprotein IIb/IIIa receptor antagonists and intracoronary metallic stents.

Main Results:

  • Animal models have been instrumental in understanding restenosis biology and testing interventions.
  • Glycoprotein IIb/IIIa inhibitors and intracoronary stents have emerged as promising therapies.
  • Both strategies, when used independently, demonstrate a 20-30% reduction in clinical restenosis at 6-month follow-up.

Conclusions:

  • Current therapeutic strategies, including glycoprotein IIb/IIIa inhibitors and intracoronary stents, significantly reduce restenosis rates.
  • Continued research into the biological processes of restenosis and refinement of treatments hold promise for preventing recurrence.
  • The ultimate goal is to achieve complete prevention of coronary stenosis recurrence after angioplasty.